Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature

Immunologic Research

Volumn 65, Issue 1, 2017, Pages 186-192

  Fenoglio, Roberta ^a   Naretto, Carla ^a   Basolo, Bruno ^a   Quattrocchio, Giacomo ^a   Ferro, Michela ^a   Mesiano, Paola ^a   Beltrame, Giulietta ^a   Roccatello, Dario ^a  

^a S GIOVANNI BOSCO HOSPITAL   (Italy)

Author keywords

ANCA associated vasculitis; B cell depletion therapy; Henoch Schonlein purpura nephritis; Henoch Schonlein treatment; IgA vasculitis; Rituximab

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FIBRINOGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HEMATURIA; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; LEUKOCYTOCLASTIC VASCULITIS; MALE; MESANGIUM CELL; MICROSCOPY; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; PSYCHOSIS; PURPURA; RECTUM HEMORRHAGE; RELAPSE; SINGLE DRUG DOSE; SKIN BIOPSY; SYSTEMIC VASCULITIS; YOUNG ADULT; ANAPHYLACTOID PURPURA; CASE REPORT; NEPHRITIS;

ADULT; AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEPHRITIS; PURPURA, SCHOENLEIN-HENOCH; RITUXIMAB; YOUNG ADULT;

EID: 84979296587     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-016-8827-5     Document Type: Article

References (58)

1. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–92.
2. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.
3. Pillebout E, Nochy D, Thervet E. Henoch–Shönlein purpura. Nephrol Ther. 2009;5(7):663–75.
4. Yang YH, Yu HH, Chiang BL. The diagnosis and classification of Henoch–Schönlein purpura: an updated review. Autoimmun Rev. 2014;13(4–5):355–8.
5. Saulsbury FT. Henoch–Schönlein purpura. Curr Opin Rheumatol. 2010;22(5):598–602.
6. Pillebout E, Verine J. Henoch–Schönlein purpura in the adult. Rev Med Interne. 2014;35(6):372–81.
7. Calvo-Río V, Loricera J, Mata C, Martín L, Ortiz-Sanjuán F, Alvarez L, et al. Henoch–Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center. Medicine (Baltimore). 2014;93(2):106–13.
8. Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch–Schönlein purpura: a comparison between the 2 disorders. J Rheumatol. 1992;19(5):721–8.
9. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, et al. Outcome of Henoch–Schönlein purpura 8 years after treatment with a placebo or prednisone at disease onset. Pediatr Nephrol. 2012;27(6):933–9.
10. Audemard-Verger A, Pillebout E, Guillevin L, Thervet E, Terrier B. IgA vasculitis (Henoch–Shönlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev. 2015;14(7):579–85.
11. KDIGO clinical practice guideline for glomerulonephritis. Chapter 11: Henoch–Schönlein purpura nephritis. Kidney Int Suppl 2012;2:218–20.
12. Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, Ormälä T, Turtinen J, Nuutinen M. Early prednisone therapy in Henoch–Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006;149(2):241–7.
13. Dudley J, Smith G, Llewellyn-Edwards A, Tizard E. Randomized placebo controlled trial to assess the role of early prednisone on the development and progression of Henoch–Schonlein purpura nephritis. Pediatr Nephrol. 2007;22:1457.
14. Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383]. BMC Med. 2004;2:7.
15. Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, Hejazi S, Noroozi M, Macooie AA. Treatment of severe Henoch–Schonlein purpura nephritis with mycophenolate mofetil. Saudi J Kidney Dis Transplant. 2014;25(4):858–63.
16. Ohara S, Kawasaki Y, Miyazaki K, Ono A, Suzuki Y, Suyama K, et al. Efficacy of cyclosporine A for steroid-resistant severe Henoch–Schönlein purpura nephritis. Fukushima J Med Sci. 2013;59(2):102–7.
17. Floege J, Feehally J. Treatment of IgA nephropathy and Henoch–Schönlein nephritis. Nat Rev Nephrol. 2013;9(6):320–7.
18. Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A. Mycophenolate mofetil: What is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev. 2007;6(3):190–5.
19. Halling SE, Söderberg MP, Berg UB. Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience. Pediatr Nephrol. 2009;24(1):91–7.
20. Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev. 2013;12(8):793–5.
21. Kattah AG, Fervenza FC, Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013;12(8):854–9.
22. Isenberg DA. Rituximab—it was the best of times, it was the worst of times. Autoimmun Rev. 2012;11(11):790–1.
23. Kamal A, Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun Rev. 2014;13(11):1094–101.
24. Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, Di Simone D, Simoncini M, Menegatti E. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment—clinical response compared to literature and immunological re-assessment. Autoimmun Rev. 2015;14(12):1123–30.
25. Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein–Henoch purpura nephritis. Pediatr Nephrol. 1998;12(3):238–43.
26. Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, et al. Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol. 2015;26(4):976–85.
27. Sinico RA, Di Toma L, Radice A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev. 2013;12(4):477–82.
28. Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Autoimmun Rev. 2012;11(9):646–52.
29. Rutgers A, Kallenberg CG. Refractory vasculitis. Autoimmun Rev. 2011;10(11):702–6.
30. Dumoitier N, Terrier B, London J, Lofek S, Mouthon L. Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev. 2015;14(11):996–1004.
31. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Roccatello D, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev. 2011;10(8):444–54.
32. Pani A, Roccatello D, Fervenza F, Lin J, Sethi S. IgA nephropathy and Schonlein–Henoch purpura nephritis. In: Singh A, editor. Core concepts in parenchymal kidney disease. New York: Springer; 2014.
33. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 “what do B-cells do?”. Clin Immunol (Orlando, FL). 2005;117(3):207–13.
34. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol (Baltimore, MD: 1950). 2003;171(3):1581–7.
35. Ozen S, Pistorio A, Lusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Paediatric Rheumatology International Trials Organisation (PRINTO). Ann Rheum Dis. 2010;69(5):798–806.
36. Bluman J, Goldman RD. Henoch–Schönlein purpura in children: limited benefit of corticosteroids. Can Fam Physician. 2014;60(11):1007–10.
37. Kato-Okada S, Suzuki H, Inoue T, Kikuta T, Okada H. Successful prednisolone therapy in elderly patients with severe forms of Henoch–Schönlein purpura nephritis. Jpn Clin Med. 2015;6(6):5–7.
38. Chartapisak W, Opastiraku S, Willis NS, Craig JC, Hodson EM. Prevention and treatment of renal disease in Henoch–Schönlein purpura: a systematic review. Arch Dis Child. 2009;94(2):132–7.
39. Zaffanello M, Fanos V. Treatment-based literature of Henoch–Schönlein purpura nephritis in childhood. Pediatr Nephrol. 2009;24(10):1901–11.
40. Bogdanović R. Henoch-Schönlein purpura nephritis in children: risk factors, prevention and treatment. Acta Paediatr. 2009;98(12):1882–9.
41. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, Jahnukainen T, Rajantie J, Ormälä T, Nuutinen M. Clinical course of extrarenal symptoms in Henoch–Schonlein purpura: a 6-month prospective study. Arch Dis Child. 2010;95(11):871–6.
42. Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P, et al. Cyclosporine A vs. methylprednisolone for Henoch–Schönlein nephritis: a randomized trial. Pediatr Nephrol. 2011;26(12):2159–66.
43. Roccatello D, Ferro M, Coppo R, Giraudo G, Quattrocchio G, Piccoli G. Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy. Nephrol Dial Transplant. 1995;10(11):2054–9.
44. Shenoy M, Ognjanovic MV, Coulthard MG. Treating severe Henoch–Schönlein and IgA nephritis with plasmapheresis alone. Pediatr Nephrol. 2007;22(8):1167–71.
45. Gianviti A, Trompeter RS, Barratt TM, Lythgoe MF, Dillon MJ. Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis. Arch Dis Child. 1996;75(3):186–90.
46. Han F, Chen LL, Ren PP, Le JY, Choong PJ, Wang HJ, et al. Mycophenolate mofetil plus prednisone for inducing remission of Henoch–Schönlein purpura nephritis: a retrospective study. J Zhejiang Univ Sci B. 2015;16(9):772–9.
47. Quartuccio L, Zuliani F, Corazza L, Scaini P, Zani R, Lenzi M, et al. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: long-term follow up data of a randomized controlled multicentre study. J Autoimmun. 2015;63:88–93.
48. Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev. 2011;11(1):48–55.
49. Yang YH, Chuang YH, Wang LC, Huang HY, Gershwin ME, Chiang BL. The immunobiology of Henoch–Schönlein purpura. Autoimmun Rev. 2008;7(3):179–84.
50. Wierciński R, Zoch-Zwierz W, Wasilewska A, Tomaszewska B, Winiecka W, Stasiak-Barmuta A, et al. Lymphocyte subpopulations of peripheral blood in children with Schönlein–Henoch purpura and IgA nephropathy. Pol Merkur Lekarski. 2001;10(58):244–6.
51. Sun XC, Chen MY, Cheng AS, Xu DL. Immunologic changes in children with Henoch–Schonlein purpura in the acute stage. Chin Med J (Engl). 1989;102(7):533–6.
52. Bellan M, Pirisi M, Sainaghi PP. Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab. Scand J Rheumatol. 2015;27:1–2.
53. Ishiguro H, Hashimoto T, Akata M, Suzuki S, Azushima K, Kobayashi Y, et al. Rituximab treatment for adult purpura nephritis with nephrotic syndrome. Intern Med. 2013;52(10):1079–83.
54. Pindi Sala T, Michot JM, Snanoudj R, Dollat M, Estève E, Marie B, et al. Successful outcome of a corticodependent Henoch–Schönlein purpura adult with rituximab. Case Rep Med. 2014;2014:619218.
55. Pillebout E, Rocha F, Fardet L, Rybojad M, Verine J, Glotz D. Successful outcome using rituximab as the only immunomodulation in Henoch–Schonlein purpura: case report. Nephrol Dial Transplant. 2011;26(6):2044–6.
56. Donnithorne KJ, Atkinson TP, Hinze CH, Nogueira JB, Saeed SA, Askenazi DJ, et al. Rituximab therapy for severe refractory chronic Henoch–Schönlein purpura. J Pediatr. 2009;155(1):136–9.
57. Hinze CH, Colbert RA. B-cell depletion in Wegener’s granulomatosis. Clin Rev Allergy Immunol. 2008;34(3):372–9.
58. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.